Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $45

Benzinga · 12/30/2025 12:57
Wells Fargo analyst Benjamin Burnett maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and lowers the price target from $65 to $45.